University of Texas Southwestern (UTSW) is one of seventeen type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Perrin White, MD, the TrialNet team at UTSW is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by Zoe Raleigh, MD, the TrialNet team at University of Utah is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Vanderbilt University Medical Center is one of seventeen type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Bill Russell, MD, the TrialNet team at Vanderbilt is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by Dr. Bryce Nelson, MD, PhD, the TrialNet team at Virginia Commonwealth University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Walter and Eliza Hall Institute of medical research in collaboration with The Royal Melbourne Hospital is one of seventeen type 1 diabetes TrialNet international clinical centers at the forefront of type 1 diabetes research. Led by Dr Peter Colman and Dr John Wentworth the TrialNet team at WEHI/RMH is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

The Wendy Novak Diabetes Institute, part of Norton Children’s and affiliated with the University of Louisville School of Medicine, is one of the major TrialNet Affiliates at the forefront of type 1 diabetes research. Led by Kupper Wintergerst MD, the TrialNet team at the Wendy Novak Diabetes Institute is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Yale is one of seventeen Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by our Clinical Center Director and Principal Investigator, Kevan Herold, MD, the TrialNet team at Yale is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.